PRODUCT INFORMATION LEAFLET

Dated: 04th April 2023

1. Product Name

Brand Name: Otrivin Moist P (Moisturising Nasal Drops)

Generic Name: Xylometazoline Hydrochloride and Sorbitol Nasal Drops I.P.

2. Qualitative & Quantitative Composition

Contains:

Xylometazoline Hydrochloride I.P..... 0.05% w/v

Sorbitol Solution (70 %) I.P. ... 2.0% w/v

(Non-Crystallising)

In an aqueous buffered vehicle containing Hydroxypropyl Methylcellulose

Preservative:

Benzalkonium Chloride IP...... 0.01% w/v

3. Dosage Form

Nasal Drops

4. Clinical Particulars

4.1. Uses/ Indications

Nasal decongestant. For the relief of blocked nose caused by colds, hay fever or other allergic rhinitis, sinusitis etc.

4.2. Posology and method of administration

Otrivin Moist P (Moisturising Nasal Drops) is indicated in children aged 1 to 11 years old only under adult supervision. Otrivin Moist P (Moisturising Nasal Drops) is to be used as nasal drops. The dose is as follows:

Children 1 to 5 years of age
1 to 2 drops into each nostril, once or twice daily (every 8

to 10 hours)

Children 6 to 11 years of age- 2 to 4 drops into each nostril, 2 to 3 times daily as needed

Do not exceed 3 applications daily into each nostril. It is recommended to make the last application shortly before retiring to bed. Otrivin Moist P (Moisturising Nasal Drops) should not be used for more than 10 consecutive days. If symptoms persist, consult your doctor. Prolonged or excessive use may cause stuffiness in the nose to return or worsen.

Instructions to administer Otrivin Moisturising are as below -

- 1. Clear the nose.
- 2. Before using, practice using the dropper to develop good dosage control.
- 3. Tilt the child's head back as far as is comfortable or, if lying on a bed, hang the head over the side.

In line with Xylometazoline hydrochloride GDS Version 3.0 (18th Jan 2023) Page 1 of 4

4. Apply the drops into each nostril and keep the head tilted back for a short time to allow the drops to spread throughout the nose.

Dated: 04th April 2023

- 5. If the drop completely misses the nose, administer the drop again.
- 6. If any part of the drop gets into the nose, do not administer the drop again.
- 7. Clean and dry the dropper before replacing it back onto the bottle right after use.
- 8. To avoid possible spread of infection, the bottle should only be used by one person.

4.3. Contra-indications

Otrivin Moist P (Moisturising Nasal Drops) should not be used if:

- Child is below 1 year of age.
- Child is allergic to xylometazoline or any other ingredients of this medicine
- Child has undergone recent trans-nasal surgery (brain surgery where the operation was carried out through the nose or mouth)
- Child is suffering from narrow angle glaucoma (increased pressure in eyes)
- Child has chronic nasal inflammation with very dry nasal passages (rhinitis sicca or atrophic rhinitis).

4.4. Warnings and Precautions

Otrivin Moist P (Moisturising Nasal Drops), like other sympathomimetic agents, should be used with caution in children showing a strong reaction to adrenergic substances, as manifested by signs of insomnia, dizziness, tremor, cardiac arrhythmias or elevated blood pressure. Consult your doctor in case of any such signs/symptoms.

Otrivin Moisturising should be used with caution in case of any of the below mentioned condition/s:

- Hypertension, cardiovascular disease
- Hyperthyroidism, diabetes mellitus, phaeochromocytoma
- Prostatic hypertrophy
- Taking or have taken monoamine oxidase inhibitors (MAOI) in the last two weeks Or taking tri-cyclic and tetra-cyclic antidepressants.

In case suffering from any of the above-mentioned condition/s, please consult your doctor before using Xylometazoline nasal drops.

Do not exceed the recommended dose. If you forget to use Otrivin Moist P (Moisturising Nasal Drops), do not take a double dose to make up for a forgotten one.

There have been rare cases of posterior reversible encephalopathy (PRES)/reversible cerebral vasoconstriction syndrome (RCVS) reported with sympathomimetic drugs, including xylometazoline. Symptoms reported included sudden onset of severe headache, nausea, vomiting, and visual disturbances. Most cases improved or resolved within a few days following appropriate treatment. This product should be discontinued immediately and medical advice sought if signs/symptoms of PRES/RCVS develop.

4.5. Interaction with other medicaments and other forms of interaction

Monoamine oxidase inhibitors (MAO inhibitors): Xylometazoline may potentiate the action of monoamine oxidase inhibitors and may induce hypertensive crisis. Hence Otrivin Moisturising

In line with Xylometazoline hydrochloride GDS Version 3.0 (18th Jan 2023) Page 2 of 4

Otrivin Moist P (Moisturising Nasal Drops) PI version 9.0

is not recommended in patients who are taking or have taken MAOIs within the past two weeks.

Tri- and tetra-cyclic antidepressants: concomitant use of tri- or tetra cyclic antidepressants and sympathomimetic preparations may result in an increased sympathomimetic effect of xylometazoline and is therefore not recommended.

Dated: 04th April 2023

4.6. Pregnancy and lactation

Not Applicable

4.7. Effects on ability to drive and use machines, if contra-indicated

Otrivin Moisturising has no effect on the ability to drive and use machines.

4.8. Undesirable effects/side effects

Stop Otrivin and tell your doctor immediately if you experience these:

- Common (may affect up to 1 in 10 people) side effects, which include: dryness or irritation of the nasal mucosa, nausea, headache, local burning sensation,
- Very rare (may affect up to 1 in 10,000 people) side effects, which include: Allergic reactions (difficulty breathing or swallowing, swelling of the face, lips, tongue or throat), blurred vision, irregular or fast heartbeat.

4.9. Overdose

Excessive administration of topical Xylometazoline hydrochloride or accidental ingestion may cause severe dizziness, perspiration, severely lowered body temperature, headache, bradycardia, hypertension, respiratory depression, coma and convulsions. Hypertension may be followed by hypotension. Small children are more sensitive to toxicity than adults. In case of accidental ingestion/ overdosage, contact your doctor immediately.

Appropriate supportive measures should be initiated in all individuals suspected of an overdose, and urgent symptomatic treatment under medical supervision is indicated when warranted. This would include observation of the individual for several hours.

If you forget to use Otrivin Moist P (Moisturising Nasal Drops), do not take a double dose to make up for a forgotten one.

5. Pharmacological Properties and/or Mechanism of action

Xylometazoline is a sympathomimetic agent acting on alpha-adrenergic receptors in the nasal mucosa. Administered in the nose, it constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighboring regions of the pharynx. It also reduces associated

In line with Xylometazoline hydrochloride GDS Version 3.0 (18th Jan 2023) Page 3 of 4

symptoms of mucus hypersecretion and facilitates drainage of blocked secretions. This decongests nasal passages and enables patients suffering from blocked nose to breathe more easily through the nose.

Dated: 04th April 2023

Otrivin Moisturising contains Sorbitol, which is a hygroscopic agent/soothing agent that helps prevent dryness and irritation of the nasal mucosa.

6. Pharmaceutical Particulars

6.1. List of Excipients

Sodium di-hydrogen Phosphate 2H2O Disodium Hydrogen Phosphate 12H2O Disodium Edetate Sodium Chloride Methylhydroxypropylcellulose 4000 Purified Water

6.2. Incompatibilities

Not applicable

6.3. Shelf life

36 months

6.4. Special storage conditions

Keep out of reach and sight of children. Store protected from Light.

6.5. Nature and specification of the container

10ml, amber coloured glass bottle with Polystyrene droppers.

6.6. Instructions for Use and Handling

FOR EXTERNAL USE ONLY

6.7. Manufacturing License Holder

Refer pack for details

6.8. Marketed By

GlaxoSmithKline Consumer Private Limited, Patiala Road, Nabha- 147201, Punjab, India

In line with Xylometazoline hydrochloride GDS Version 3.0 (18th Jan 2023) Page 4 of 4

^{*}Trademarks are owned by or licensed to the GSK Group of companies